20:07 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample, cell culture and mouse studies suggest activating AMPK could help treat pulmonary fibrosis. In lung tissue samples from idiopathic pulmonary fibrosis (IPF) patients, fibroblast levels of activated AMPK were lower than...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc., Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
23:33 , Feb 10, 2017 |  BioCentury  |  Emerging Company Profile

Improving the original immunotherapy

Recombinant IL-2 was one of the first immunotherapies marketed for cancer but is not widely used due to severe off-target toxicities. Cue Biopharma Inc. is developing preclinical programs that deliver IL-2 only to T cells...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased efficacy....
07:00 , Aug 11, 2016 |  BC Innovations  |  Targets & Mechanisms

Niche for the aged

A pair of Nature Medicine studies has placed integrin β1 signaling at the center of post-injury muscle regeneration in elderly patients. With one study pointing to the receptor and the other to its ligand, the...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Fibronectin 1 (FN1; FN)

Musculoskeletal disease INDICATION: Tissue damage Cell culture and mouse studies suggest FN1 could help treat muscle injury in aged patients. In a mouse model of muscle injury, muscle levels of FN1 were lower in aged (20-month old)...
07:00 , Aug 27, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: A gadolinium/CREKA (Cys-Arg-Glu-Lys-Ala) peptide-based MRI agent for detection of micrometastases

Imaging TECHNOLOGY: MRI A gadolinium/CREKA-based MRI agent could help detect micrometastases of breast cancer, which have expression of fibronectin 1 (FN1; FN). The agent consisted of three molecules of a complex of gadolinium and DOTA (4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecyl) linked...
08:00 , Jan 15, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Cell-penetrating NanoFlare probes to detect circulating tumor cell (CTC) mRNA signatures

Assays and screens TECHNOLOGY: Cell-free assays NanoFlares could be used to detect CTCs from whole blood samples. NanoFlares are gold nanoparticles linked to single-stranded DNA complementary to mRNA targets and a fluorescent reporter that is activated upon...
08:00 , Jan 19, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Fibronectin 1 (FN1; FN) Mouse studies identified an FN1-targeting antibody-drug conjugate...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Clinical News

Tarceva erlotinib: Additional Phase II data

Researchers at the M.D. Anderson Cancer Center reported additional data from a subgroup of 101 stage IV NSCLC patients who had gene expression profiles obtained from pretreatment core needle biopsies in the adaptive, open-label, U.S....